Articles

A systematic review of economic burden of colorectal cancer

Abdosaleh Jafari, Fatemeh A Hosseini, Faride S Jalali et al.Health Sci Rep. 2024 Aug 21;7(8):e70002

Colorectal cancer is the third most common cancer in the Western Hemisphere. It is the third most common cancer in men after prostate and lung cancers and the second most common cancer in women after breast cancer. The data from 37 studies dealing with the costs of patients with colorectal cancer were extracted. Most o... Read More

15 Apr, 2026

Global, regional and national burden of colon and rectum cancer attributable to high fasting plasma glucose: a systematic analysis for the Global Burden of Disease Study 2021

Ke Lu and Gang Xu. Front Oncol 2026 Feb 27:16:1690349

Colorectal cancer (CRC), the third most common malignant cancer globally, imposes a substantial public health burden. Emerging evidence has highlighted hyperglycemia as an independent risk factor for CRC. Globally, high fasting plasma glucose (FPG)-related CRC deaths increased from 31,907 (1990) to 82,421 (2021), with ... Read More

15 Apr, 2026

Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death

Michael Bretthauer, Magnus Løberg, Paulina Wieszczy, et al. N Engl J Med. 2022;387:1547-1556

We performed a pragmatic, randomized trial involving presumptively healthy men and women 55 to 64 years of age drawn from population registries in Poland, Norway, Sweden, and the Netherlands between 2009 and 2014. The participants were randomly assigned in a 1:2 ratio either to receive an invitation to undergo a single... Read More

15 Apr, 2026

Screening and eradication of Helicobacter pylori for gastric cancer prevention: Taipei Global Consensus II

Jyh-Ming Liou , Peter Malfertheiner , Tzu-Chan Hong , et al. Gut. 2025 Oct 8;74(11):1767-1791

Eradication of H pylori, the primary cause of gastric cancer, reduces the risk of gastric cancer across all age groups, with the greatest risk reduction before the onset of premalignant conditions. H pylori eradication also promotes ulcer healing, prevents ulcer recurrence and reduces the risk of NSAID/aspirin related ... Read More

15 Apr, 2026

Tyrer-Cuzick Lifetime Risk Is Not Associated With Non-BRCA1/2 Pathogenic Variants for Breast Carcinoma

Divya Rao , Chloe Wernecke, Lisa Baron, et al. Breast J. 2026 Jan 19:2026:8670441

The Tyrer-Cuzick (TC) or IBIS risk calculator is a widely used tool to estimate the probability of developing breast cancer. The TC is commonly used to guide patients toward further diagnostic imaging, genetic testing, chemoprevention, or risk-reducing surgery. A population of 964 patients with TC was evaluated for 12 ... Read More

15 Apr, 2026

Breast cancer genetics and risk assessment: an overview for the clinician

L Larkin. Climacteric. 2023 Jun;26(3):229-234

Breast cancer is the most common cancer in women globally with enormous associated morbidity, mortality and economic impact. Prevention of breast cancer is a global public health imperative. To date, most of our global efforts have been directed at expanding population breast cancer screening programs for early cancer ... Read More

15 Apr, 2026

Breast cancer statistics 2024

Angela N Giaquinto , Hyuna Sung , Lisa A Newman , et al CA Cancer J Clin. 2024 Nov-Dec;74(6):477-495

Breast cancer incidence continued an upward trend, rising by 1% annually during 2012-2021, largely confined to localized-stage and hormone receptor-positive disease. A steeper increase in women younger than 50 years (1.4% annually) versus 50 years and older (0.7%) overall was only significant among White women. Asian A... Read More

15 Apr, 2026

Global burden, trends, and attributable risk factors of women's cancers with projection to 2050: Results from the GLOBOCAN 2022 and global burden of disease study 2021

Tingting Wei , Yunhai Li , Ze Zhang , et al. Eur J Surg Oncol. 2026 Mar 7;52(5):111742

Women's cancers pose a significant global health burden, with pronounced geographical and age-related disparities. Targeting modifiable risk factors and enhancing healthcare access, especially in low-SDI regions, is essential to reducing the worldwide burden of women's cancers. In 2022, there were 3.7 million new cases... Read More

15 Apr, 2026

The global epidemic of early-onset cancer: nature, nurture, or both?

S. Ogino and T. Ugai. Annals of Oncol;.35(12) 1071-1073. 2024

The incidence of early-onset cancer (EOC) diagnosed in individuals under the age of 50 has been increasing worldwide, which may be just the tip of the iceberg of larger emerging issues, including the rise of various chronic diseases across multiple generations. While this phenomenon was first recognized in colorectal c... Read More

15 Apr, 2026

Trends in the disease burden of early-onset cancers in China from 1990 to 2021: a systematic analysis of the 2021 Global Burden of Disease study

Jicun Zhu, Tiandong Li, Jiajun Chen, et al. BMC Cancer. 2025 Jul 12;25(1):1168

In recent years, the incidence of early-onset cancers among individuals under 50 years of age has been on the rise. From 1990 to 2021, the incidence rate of all early-onset cancers in China increased by 150.72 per 100,000, while the mortality and disability-adjusted life years (DALY) rates decreased by 4.30 per 100,000... Read More

15 Apr, 2026